BMRN241018C65000
- 4.79
- -0.71-12.91%
Biomarin Pharmaceutical Newsroom
Goldman Sachs Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $139
Truist Financial Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $90
Citi Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Maintains Target Price $93
Wells Fargo Initiates Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $90
Barclays Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $110
Barclays Remains a Buy on BioMarin Pharmaceutical (BMRN)
CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Maintains Target Price $93
A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $72 to $115
Hold Rating on BioMarin Pharmaceutical Amid Competitive Dynamics and Market Penetration Nuances for Voxzogo
BioMarin Pharmaceutical Price Target Cut to $90.00/Share From $115.00 by Wells Fargo
A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $78 to $122
BioMarin Pharmaceutical Is Maintained at Buy by Stifel
Biomarin Pharmaceutical Analyst Ratings
BioMarin Pharmaceutical (BMRN) Receives a Buy From Truist Financial
RBC Cuts Price Target on BioMarin Pharmaceutical to $85 From $100, Keeps Sector Perform Rating
Barclays Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $110
Barclays Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical Is Maintained at Hold by Canaccord Genuity
BioMarin Pharmaceutical Price Target Maintained With a $93.00/Share by Canaccord Genuity
CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Maintains Target Price $93